logo-loader
RNS
EMV Capital

AMR BIO: CONSTRUCTIVE TYPE B FDA MEETING FOR XF-73

RNS Number : 1861D
EMV Capital PLC
16 November 2026
 

REACH: For release at 07.00 a.m. on 16 November 2026

 

EMV Capital plc

(EMVC, Group or the Company)

 

EMV CAPITAL PORTFOLIO COMPANY AMR BIO

CONSTRUCTIVE TYPE B FDA MEETING FOR XF-73 NASAL PHASE 3 TRIAL DESIGN

Milestone achieved within c.14 months of AMR Bio’s formation through EMV Capital’s Venture Build programme

 

EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that its portfolio company, AMR Bio, has received the official meeting minutes from its Type B End-of-Phase 2 (EOP2) meeting with the US Food and Drug Administration (FDA).

AMR Bio is a clinical-stage biotechnology company developing new treatments to prevent infections without contributing to antimicrobial resistance. At the EOP2 meeting AMR Bio discussed the design of its proposed Phase 3 programme for its lead product, XF-73 Nasal.

AMR Bio is part of EMVC’s Venture Build programme. Following the formation of AMR Bio in September 2025 EMVC holds a direct interest of 29.7%, with further interests by private investors from EMVC’s EIS Syndicate and Fund.

The FDA Type B meeting follows the previously reported successful completion of a Phase 2b clinical study in patients undergoing open-heart surgery, in which XF-73 achieved a 99.5% reduction in Staphylococcus aureus nasal carriage before surgery.

The FDA was supportive of the Phase 3 trial design proposed by AMR Bio and provided recommendations that will inform the final Phase 3 trial design for XF-73 Nasal. AMR Bio will now incorporate the FDA’s recommendations into its clinical development plans and expects to submit full Phase 3 protocols to the FDA in the coming months.

XF-73 is a first-in-class antimicrobial nasal gel being developed for use in the 24 hours before surgery to reduce the nasal burden of Staphylococcus aureus, including MRSA, to prevent post-operative surgical site infections. Its novel mechanism of action disrupts the bacterial cell membrane and has shown a low propensity for resistance development, offering a potential alternative to conventional antibiotics in pre-surgical infection prevention.

XF-73 Nasal holds Qualified Infectious Disease Product (QIDP) designation and Fast Track status from the FDA, which provides an additional five years of US market exclusivity and eligibility for priority review and rolling submission. In the UK, XF-73 Nasal has been granted an Innovation Passport under the MHRA’s Innovative Licensing and Access Pathway (ILAP).

Nigel Brooksby, Executive Chair of AMR Bio, commented:

"This is an important milestone for XF-73 Nasal. We are very encouraged by the outcome of our EOP2 meeting and the FDA's supportive feedback on our proposed Phase 3 trial design. This gives us greater clarity as we finalise the protocols for our two planned pivotal trials.

"Post-operative surgical site infections remain a significant clinical and economic burden, and the challenge is growing as antimicrobial resistance spreads. Our Phase 2b results showed XF-73's ability to substantially reduce nasal carriage of Staphylococcus aureus before surgery and we believe it offers considerable potential to reduce the risk of post-operative surgical site infections. Our immediate priority is to incorporate the FDA's recommendations and move the Phase 3 programme forward as quickly as possible, next progressing our CMC and CRO strategy."

Dr Ilian Iliev, CEO of EMV Capital plc, commented:

"AMR Bio continues to demonstrate the strength of its lead asset, XF-73 Nasal, and this latest regulatory development marks another step towards bringing the product to market.

“This milestone shows our Venture Build model working as intended, using a capital efficient structure and a lean team to derisk an investment proposition. In just over a year, AMR Bio has transferred the US IND, secured ILAP status in the UK and now received FDA feedback supporting its Phase 3 design.

“This is what capital-efficient value creation looks like: removing key risks at each stage before larger amounts of capital are committed.

“From an investment perspective, we see a highly attractive opportunity with lots of upside potential. With few new classes of antimicrobials developed in recent decades, there is a clear commercial imperative for innovative approaches to infection prevention before antibiotics need to be prescribed. We believe AMR Bio is well positioned to capitalise on this demand and look forward to supporting the business through its next phase of growth."

- ends -

 

For more information, please contact:

 

EMV Capital plc

via Rosewood

Ilian Iliev, CEO

 

 

 

Shore Capital (Broker)

+44 (0)20 7408 4090

Mark Percy / Fiona Conroy

 

 

Rosewood (Financial PR)

 

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Sutton

 

 

About EMV Capital plc (EMVC)

EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, EMV Capital invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

                capital-efficient investments through Group balance sheet;

                fund management of the Evergreen EIS and Martlet Capital Funds;

                syndicated investments leveraging its network of third-party investors.

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on AIM, a market operated by the London Stock Exchange.

www.emvcapital.com

 

About AMR Bio

AMR Bio is a clinical phase biotechnology company dedicated to infection prevention, advancing XF-73, a first-in-class topical antimicrobial designed to prevent post-surgical infections.

The company’s lead product, XF-73 Nasal, has demonstrated strong clinical efficacy in a Phase 2b study and is advancing towards Phase 3 development for the prevention of Staphylococcus aureus infections in surgical settings. The unique attributes of this product mean it could become the market leader for pre-surgery decolonisation.

AMR Bio’s proprietary XF platform also supports dermal applications targeting severe wound and skin infections, representing a significant adjacent market opportunity exceeding $20 billion. XF-73 Dermal has been granted Qualified Infectious Disease Product (QIDP) designation by the US FDA for burn wound infections, supporting accelerated development and extended market exclusivity.

AMR Bio is focused on progressing XF-73 through late-stage development, building strong clinical data packages, and seeking partners for the final clinical studies and commercialisation.

For more information, visit: https://amr-bio.com/ 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRADXLFFQFLBFBL
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Metals One, Critical Mineral Resources, Ariana Resources, IXICO, EMV...

Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF) is targeting uranium recovery from historic mine waste in Colorado's Uravan Belt with zero capex exposure, thanks to its partnership with DISA Technologies.  Gamma data is due by end of May and assay results by Q3, with a potential revenue stream...

on 05/23/2026

6 min read